anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Icenticaftor (QBW251) is a potentiator of the cystic fibrosis transmembrane receptor. Based on its mechanism of action, icenticaftor is expected to provide benefits in patients with chronic obstructive pulmonary disease by restoring mucociliary clearance, which would eventually lead to a reduction of bacterial colonization and related inflammatory cascade. A placebo- and positive-controlled, 4-way crossover thorough QT study was conducted in 46 healthy participants with the objective to assess the effect of therapeutic (300 mg twice daily for 6 days) and supratherapeutic (750 mg twice daily for 6 days) oral doses of icenticaftor on electrocardiogram parameters, including concentration-corrected QT (QTc) analysis. Moxifloxacin (400 mg, oral) was used as a positive control. In the concentration-QTc analysis performed on pooled data from Day 1 and Day 6 (steady state), the estimated population slope was shallow and slightly negative: -0.0012 ms/ng/mL. The effect on the Fridericia corrected QT (QTcF) interval (∆ΔQTcF) was predicted to be -1.3 milliseconds at the icenticaftor 300-mg twice-daily peak concentration (geometric mean was 1094 ng/mL) and -5.5 milliseconds at the 750-mg twice-daily peak concentration (geometric mean Cmax was 4529 ng/mL) indicated a mild shortening effect of icenticaftor on QTcF interval length. The results of the by-time-point analysis indicated least squares placebo corrected mean ∆∆QTcF across time points ranged from -7.9 to 0.1 milliseconds at 1 and 24 hours after dosing both on Day 6 in the 750-mg dose group compared with -3.7 to 1.6 milliseconds at 1.5 and 24 hours after dosing on Day 1 in the 300-mg dose group. Assay sensitivity was demonstrated with moxifloxacin. The large accumulation of exposures, especially the 4.3-fold increase in peak plasma concentration observed at the icenticaftor 750-mg twice-daily dosage compared with Icenticaftor 300 mg twice daily (2.3-fold) on Day 6 provided a large concentration range (up to 9540 ng/mL) to evaluate the effect of icenticaftor on ΔΔQTcF. Based on the concentration-QTc analysis, an effect on ΔΔQTcF exceeding 10 milliseconds can be excluded within the full observed ranges of plasma concentrations on icenticaftor, up to approximately 9540 ng/mL. Icenticaftor at the studied doses demonstrated a mild shortening in QTcF, which is unlikely to be of clinical relevance in a therapeutic setting.
PURPOSE OF REVIEW: This review aims to provide a comprehensive overview of the current understanding of genetic markers associated with heart failure (HF) and its underlying causative diseases, such as cardiomyopathies. It highlights the relevance of genetic biomarkers in diagnosing HF, predicting prognosis, potentially identifying its preclinical stages and identifying targets to enable the implementation of individualized medicine approaches.
RECENT FINDINGS: The prevalence of HF is increasing due to an aging population but with greater access to disease-modifying therapies. Advanced diagnostic tools such as cardiac magnetic resonance, nuclear imaging, and AI-enabled diagnostic testing are now being utilized to further characterize HF patients. Additionally, the importance of genetic testing in HF diagnosis and management is increasingly being recognized. Genetic biomarkers, including single nucleotide polymorphisms (SNPs) and rare genetic variants, are emerging as crucial tools for diagnosing HF substrates, determining prognosis and increasingly directing therapy. These genetic insights are key to optimizing HF management and delivering personalized treatment tailored to individual patients. HF is a complex syndrome affecting millions globally, characterized by high mortality and significant economic burden. Understanding the underlying etiologies of HF is essential for improving management and clinical outcomes. Recent advances highlight the use of multimodal assessments, including AI-enabled diagnostics and genetic testing, to better characterize and manage HF. Genetic biomarkers are particularly promising in identifying preclinical HF stages and providing personalized treatment options. The genetic contribution to HF is heterogeneous, with both monogenic and polygenic bases playing a role. These developments underscore the shift towards personalized medicine in HF management.
OBJECTIVE: To compare prostate artery embolisation (PAE) to the combination of tamsulosin and dutasteride therapy as a potential first-line therapy for obstructive benign prostatic hyperplasia (BPH) in treatment-naïve patients in the 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE).
PATIENTS AND METHODS: A total of 39 men with enlarged prostates, moderate-severe lower urinary tract symptoms (LUTS) and obstructed/equivocal urodynamic studies (UDS), and who had no prior treatment for BPH, were randomised to receive either combined medical therapy with tamsulosin and dutasteride (medication) or PAE. Follow-up UDS, International Prostate Symptom Score (IPSS), uroflowmetry and ultrasound were performed at short- to medium-term intervals following interventions and compared to baseline.
RESULTS: The medication and PAE treatment groups had similar baseline characteristics, including prostate volumes (87.8 and 85.4 mL respectively), maximum urinary flow rate (Qmax; 6.5 and 6.6 mL/s, respectively), IPSS (19.5 and 21, respectively) and obstructed UDS (79% and 74%, respectively). Both interventions improved voiding and bladder outflow obstruction from baseline, with more patients unobstructed after PAE (63%) compared to medication (28%) (P = 0.03). PAE patients had significantly greater reductions in prostate size (P < 0.001), incomplete emptying (P = 0.002), total IPSS (P = 0.032), Qmax (P = 0.006) and quality of life (P = 0.001). Altered ejaculation, erectile dysfunction and nausea were more common in the medication group.
CONCLUSION: Prostate artery embolisation was more effective than combined medical therapy at reducing urinary obstruction, decreasing prostate volume and improving LUTS in patients with BPH who had not previously been treated. This is the first randomised control study to compare PAE and combined medical therapy in exclusively treatment-naïve patients and raises the potential of PAE as an alternative early treatment option for BPH. Further randomised comparative trials are planned to further validate the role of PAE in mitigating obstructive BPH.
Evidence-based psychosocial treatments have recently been developed. However, very little data exist on the use of pharmacotherapy for adolescents SUD (Substance Use Disorder). One promising pharmacotherapy approach is to treat co-occuring psychiatric disorders. A common co-occurring disorder in adolescent SUD is attention-deficit/hyperactivity disorder (ADHD). Fortunately, new ADHD medications, such as atomoxetine, that do not have addictive potential are now available. However, all controlled studies of atomoxetine have specifically excluded teens with SUD. Therefore, little data exist on the safety and efficacy of the medication in this population. This research project will address the important research gap with the specific aim: to conduct a randomized, placebo-controlled trial of atomoxetine for ADHD in teens with SUD.
Among other things, a respiratory support score is determined. Operating parameters of one or more respiratory support devices associated with a patient are received. Based on the operating parameters, a respiratory support type associated with the patent is determined. A score range for the respiratory support type is received, and a respiratory support score within the range is determined based on at least a subset of the operating parameters. In another aspect, a medication efficacy score is determined. A time point corresponding to a clinical action performed on a patient is identified, the clinical action including administration of a drug at a particular dosage. Parameters indicative of a clinical condition of the patient are tracked for a time range that includes the time point corresponding to the clinical action. Based on the parameters, a metric indicative of an efficacy of the clinical action performed on the patient is determined.
BACKGROUND: Elderly patients and their surgeons may eschew shoulder arthroplasty due to concerns over patient safety and longevity. The purpose of this study was to review the current literature evaluating the clinical and radiographic outcomes of shoulder arthroplasty performed in patients 80 years and older.
METHODS: A literature search of the Embase, PubMed, Medline, and Cochrane databases was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies evaluating the outcomes of primary and revision anatomic (aTSA) and reverse (RSA) total shoulder arthroplasty in patients 80 years and older were included for analysis.
RESULTS: A total of 15 studies evaluating 1685 primary aTSAs, 1170 primary RSAs, 69 RSAs performed for fracture, and 45 revision RSAs were included for review. The postoperative active forward flexion and external rotation ranged from 138° to 150° and 45° to 48° after aTSA and from 83° to 139° and 16° to 47° after RSA, respectively. Postoperative visual analog scale pain scores ranged from 0 to 1.8 after aTSA and from 0 to 1.4 after RSA. Ninety-day mortality ranged from 0% to 3%, and perioperative complications ranged from 0% to 32%. Late complications ranged from 5.6% to 24% for aTSA patients and 3.5% to 29% for patients undergoing RSA for all indications. Common complications included glenoid loosening (0%-18%) and rotator cuff tear (5.6%-10%) after aTSA and scapular notching (0%-40%) and scapular fracture (4%-9.4%) after RSA. Reoperation rates ranged from 0% to 6% after aTSA and from 0% to 13% after RSA.
CONCLUSIONS: aTSA and RSA in this population are safe and effective, demonstrating low rates of perioperative mortality and reoperation, durability that exceeds patient longevity, satisfactory postoperative range of motion, and excellent pain relief. Late complication rates appear to be similar for aTSA and RSA.
The objectives of tis study are to rigorously evaluate the effect of Tribal Turning Point (TTP) on diabetes risk factors in Native youth. The investigators will enroll up to 360 youth who are aged 7-10 years, overweight/obese (BMI \>85th percentile), self-identify as American Indian, and have \>1 parent/primary caregiver willing to actively participate in the program. Within each community, youth will be randomized to the TTP program or a general health and safety control program. The multi-component TTP intervention is a youth-centered adaptation of the Diabetes Prevention Program designed to reduce diabetes risk factors by improving activity and dietary behaviors. Informed by the pediatric weight management literature, the 12-month intervention includes 12 active learning group classes, 7 individual youth/parent motivational interviewing counseling sessions, and community-specific resource toolboxes. In this trial, the investigators will assess the effect of TTP on anthropometric, metabolic, and behavioral risk factors for type 2 diabetes at the end of the intervention (12mo) and after 1 year of follow-up (24mo).
The invention relates to a skin protecting health-care pure traditional Chinese medicine composition which belongs to the technical field of curative activity of compounds or pharmaceutical preparations in medical division in living needs of human according to International Patent Classification (IPC). The invention relates to a skin protecting health-care traditional Chinese medicine composition, and in particular relates to a pure traditional Chinese medicine composition for preventing and treating various discomforts and sore itch of skin. The composition is prepared from the following natural pure traditional Chinese medicines free from toxic and side effects in preferable proportion: periostracum cicada, mother chrysanthemum, goldthread root, Scutellaria baicalensis, golden cypress, radix sophorae flavescentis, honeysuckle, fructus forsythiae, dandelion, radix lsatidis and puffball. The composition is characterized in that the pure composition has special effect to treat various discomforts and sore itch of skin. The novel technical scheme provided by the invention has wide application in the technical field of curative activity of medical pharmaceutical preparations. Clinical verification shows that the composition is a pure traditional Chinese medicine formula which remarkably treats various discomforts and sore itch of skin. The pharmaceutically acceptable auxiliary materials contained in the pharmaceutical composition provided by the invention can be officinal carriers, excipients and other additives for conventional preparations.
An article of apparel including a delivery layer and a component releasable from the layer is disclosed. In an embodiment, the apparel includes a textile base layer the delivery layer oriented to contact the skin of the wearer. The delivery layer is formed from a composition including the releasable component. In another embodiment, the textile is formed of strands coated with the releasable component. In still further embodiments, the strands are formed of the releasable component. The apparel may release the component to the skin of the wearer.
<P>PROBLEM TO BE SOLVED: To provide a method for efficiently manufacturing many collagen sheets collectively without damaging smoothness and flatness of a sheet surface.  <P>SOLUTION: After forming a collagen solution frozen layer 11 by pouring a collagen solution into a tray 10 and freezing it, a water frozen layer 12 is formed by pouring water on the collagen solution frozen layer and freezing it and then, a collagen solution frozen layer 11 is formed by pouring the collagen solution on the water frozen layer 12 to be frozen. A block 13 is formed by alternately repeating the process of forming the water frozen layer 12 and the process of forming the collagen solution frozen layer. By vacuum-drying the block 13, moisture contained in the respective collagen solution frozen layer 11 is sublimated and removed and they are changed into porous collagen sheets respectively. Additionally, the water frozen layer 12 is sublimated and removed, and the respective collagen sheets are obtained in the state of being directly laminated.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PROBLEM TO BE SOLVED: To provide a drug storage device allowing taking out drugs by only single action, returning the drugs without disturbing their rows, and appropriately grasping the storage states. SOLUTION: This drug storage device is provided with a lot of cassettes 20 for storing the drugs 1 in the aligned states and a support means 10 holding the cassettes 20 in the aligned states. The cassette 20 is formed with an exit/ entrance 21 allowing taking out the drugs 1 and pushing them thereinto, and an energizing means 22 energizing the stored drugs 1 toward the exit/entrance 21 is added thereto. The support means 10 holds the cassette 20 with the exit/ entrance 21 exposed. Counting means 41, 42, 30 for finding the number of drugs 1 stored in the cassette 20 are provided so that the drugs can be directly taken in/out from the cassette by hands, and the drugs in the respective cassettes are automatically counted.  A drug rack and a drug cart are provided so as to reduce the restriction in the establishment, forming of a supplement port can facilitate a batch supplement, and the real-time output can make the drug administration precise.
The invention relates to cosmetic or dermatological cleaning emulsions, characterized in that, in relation to the total weight of the preparations, said emulsions contain 1 to 30 wt. % of one or several detergent surfactants, selected from the group of surfactants which have a HLB value higher than 15, - 35 to 50 wt. % of one or several oil components, - 0.001 to 30 wt. % of one or several active ingredients, - 0.2 to 5 wt. % of one or several polyacrylates, selected from the group consisting of anionic homo- and/or copolymers of acrylic acid and/or alkylated acrylic acid derivatives as well as the esters thereof and 5 to 60 wt. % of water.
Sepsis is an inevitable stage of bacterial invasion characterized by an uncontrolled inflammatory response resulting in a syndrome of multiorgan dysfunction. Most conventional antibiotics used to treat sepsis are efficacious, but they have undesirable side effects. The green synthesised Ag NPs were synthesized by 5 g of the earthworm extract dissolved in a volume of 500mL of distilled water and then added to 2,500 mL aqueous solution of 1mM silver nitrate at 40 °C. After 4 h, the mixture was then allowed to dry overnight at 60 °C. Later, Ag NPs were washed and collected. They were characterized by X-ray diffraction, ultraviolet-visible spectroscopy, and transmission electron microscopy. Sepsis model as induced by feces-intraperitoneal injection method. Eighteen male mice were assigned into three main groups: the control group, the sepsis-model group, and the Ag NPs-treated group. The control group received a single oral dose of distilled water and, after two days, intraperitoneally injected with 30% glycerol in phosphate buffer saline. The Sepsis-model group received a single oral dose of distilled water. Ag NPs - The treated group received a single oral dose of 5.5 mg/kg of Ag NPs. After two days, the sepsis-model group and Ag NPs-treated group were intraperitoneally injected with 200 µL of faecal slurry. Ag NPs treatment in septic mice significantly decreased liver enzyme activities, total protein, and serum albumin. Moreover, Ag NPs significantly enhanced kidney function, as indicated by a significant decrease in the levels of creatinine, urea, and uric acid. In addition, Ag NPs showed a powerful antioxidant effect via the considerable reduction of malondialdehyde and nitric oxide levels and the increase in antioxidant content. The histopathological investigation showed clear improvement in hepatic and kidney architecture. Our findings demonstrate the protective efficacy of biogenic Ag NPs against sepsis-induced liver and kidney damage.
The invention provides a cell-specific nuclear targeting molecule having a nucleic acid sequence which includes a binding site for a nuclear DNA binding protein expressed only in a specific cell type. The invention further provides a plasmid for targeting a DNA molecule into the nuclei of a specific cell type. The plasmid comprises the cell-specific nuclear targeting molecule and a DNA molecule to be targeted to the nuclei of the specific cell type. This plasmid of the subject invention can be introduced into various host cells, and the cell-specific nuclear targeting molecule will target the DNA molecule to the nuclei of the specific cell type. Thus, the invention further provides a method of targeting a DNA molecule into the nuclei of a specific cell type. The method comprises providing a plasmid (the plasmid comprising the cell-specific nuclear targeting molecule and the DNA molecule to be targeted) and introducing the plasmid into the cytoplasm of the specific cell type. In this method, the cell-specific nuclear targeting molecule targets the DNA molecule into the nuclei of the specific cell type.
The invention discloses a Chinese composition used for treating puffiness and edema. The preparation materials of effective components are 15 to 45 parts of loosestrife, 25 to 60 parts of Lysimachia christinae, 15 to 45 parts of Lygodium japonicum (Thunb.), 15 to 45 parts of Pteris nervosa, 15 to 45 parts of dandelion, 15 to 45 parts of umbelliferae pimpinella diversifolia and 15 to 45 parts of prunella vulgaris. In production, the effective components of the Chinese composition are extracted and mixed with a carrier acceptable for pharmacy to make various preparations. Medicines made of the Chinese composition can be used for treating the puffiness and the edema caused by various reasons. And the medicines made of the Chinese composition has the advantages of good curative effect, short treating period, low material cost and high healing rate.
A total of 16 healthy adults will be enrolled and vaccinated with a single dose of vaccine. Group 2 (N = 16) will receive a single injection of cAd3-EBO-S at 1 x 10\^11 Particle Units (PU) vaccine.
PURPOSE:To enable accurate serological examination by removing non-specific agglutination reaction due to a Forssman antibody (F-antibody) by absorbing the F-antibody in serum without performing any pretreatment, by adding the extract containing the F-antibody obtained from a kidney of an animal to serum to be examined. CONSTITUTION:Internal organs of an animal, especially, a horse is pref. used because the kidney is large and easy to obtain. Said internal organs are homogenized to be treated with acetone and the obtained extract is extracted with a solvent after dehydration while the extract is filtered and the filtrate is collected to be added to acetone and the formed precipitate is centrifugally separated and the solvent is removed under vacuum to obtain an F-antigen-containing extract. The extract is added to a salt/ phosphate buffer solution along with rabbit serum to obtain a reaction liquid which is, in turn, added to serum to be examined to make it possible to exclude non-specific agglutination reaction based on an F-antibody in serum to be examined. The solution, to which this F-containing extract was added, is stable and does not loose activity over a year or more at room temp. and, because said solution may be merely added to the serum to be examined, said solution can be used serum reaction examination simply in low cost.
Alirocumab 300 milligram (mg) subcutaneous (SC) injection on Week 0 (Day 1), self-administered using AI device, on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, participants switched to other arm of SYDNEY device to receive Alirocumab 300 mg, self- administered (unsupervised) using new auto-injector device (SYDNEY) every 4 weeks (Q4W) from Week 4 until Week 16 in the single arm treatment period added to lipid modifying therapy (LMT).
The present invention provides a method and a system for constructing a suture material for a tissue or organ defective part. The method comprises the steps of: obtaining a tissue defective position of a patient; collecting initial image data in the tissue defective position of the patient, restoring an initial 3-dimensional image in the tissue defective position and a 3-dimensinoal image in a defective part corresponding to the defective position, and generating and storing a 3-diemnsinoal model of the defective part to be sutured; performing simulation matching according to the defective part to be sutured and a model after tissue defection; and obtaining a 3-dimensional model in the defective part to be sutured, outputting a 3-dimensinoal model in the defective part to be sutured, and generating an actual model of a suture material. According to the present invention, according to the structural features of defective tissue, a defective part to be sutured is planned, designed, and formed to be matched with a conventional bio-structure. The defective part to be sutured is outputted through a 3D printer, and is used in filling and repairing a defective part. Thus, an overall tissue structure can be perfectly reproduced, and a perfect state before defection can be ensured. Also, an optional complicated defected part having a large volume or a large area can be individually repaired.
A formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for nasal administration to a subject with any known nasal administration device. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved system for administering corticosteroid intranasally. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation is provided.